Sunday, June 05, 2022 3:46:39 PM
Why was there no run-up to ASCO? Why should there be a run-up to actual TLD? As VikingInvest notes in his response to you, NWBO needs to be on an actual exchange in order to really fly. From what I gather, that means $4+ for 6 months or so. How is that going to happen? If they had managed releasing TLD as was expected, they should have been able to make it happen. But as VikingInvest also notes, they are chomping at the bit to tell the world and it appears at this juncture that once again they let their impatience get away from them and made a huge and costly mistake. Maybe they didn't, I sure don't know because the company isn't talking. So we wait to see what they say at the ASM. If they honestly thought the journal would come out about the time of NYAS, then they were off by about a month (so far). And this after Linda Powers explicitely said several years ago that releasing at ASCO was only if the timing worked out. Once again, it appears that this is not at all what happened but that they tried to squeeze something into a timeline they had no control over and blew it. Maybe there is another explanation but it is not yet forthcoming.
I am now, and have been since the start, impressed by management's ability to get the company and product this far but that does not mean that I agree with everything they have done or believe that they are perfect. Up until release of TLD I was willing to go on faith and the indications of progress. Now that TLD is out there, I am not so generous. Instead, I feel very much betrayed at present because I sat around patiently, defending the company and their 'plan,' for 20 months only to have them toss it away because it appears that they still can't keep to a script.
TLD was supposed to be a jump (even if temporary) to a more reasonable share price. Now maybe that was just me being unrealistic but that doesn't somehow make me happier. Instead, their partial release has been a big share-price bomb that has the potential to depress future rises because it is really hard to try to get friends and family, or redditor apes, to buy into a stock where promises are illusory and profits are maybe a year+ away after approval and uplisting. Without uplisting, as VikingInvest notes, don't expect a lot of institutional money. That just leaves retail, and why should retail trust the company?
So I am put into a quandary. I need to remove at least some money in the near-term (next few weeks). Do I sell at these #@(*^ prices? Alternatively, do I allow Fidelity to loan out my shares? They are offering ~$14K a month, which would help my cash-flow situation until the stock actually goes somewhere. At present I am not feeling like I owe management anything, especially as they can't be bothered to respond to correspondence. So I will wait to see if they schedule an ASM and what they are asking for and what they are providing us. But I don't see any reason to authorize share increases until they need them and they don't need them at these prices. If they want more shares, bring the share price up first. Perhaps this is all short-sighted but that just makes me a perfect market player, no?
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM